By 
Allergy Immunology Market to Hit USD 10.57 Bn by 2032
The Allergy Immunology Market was USD 4.45 Bn in 2024 and is expected to expand at a CAGR of 11.4 % from 2025 to 2032, reaching USD 10.57 Bn by 2032. Globally, allergic diseases are the epidemic due to the fast opening up to 30-40 % worldwide. Another common cause of allergic reactions is poor indoor air quality, which can be affected by pollution, Mold, and dust mites. Allergen immunotherapy treatment (AIT) [subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT)] is emerging as the most effective treatment for patients with allergic diseases. This includes biologics like omalizumab (Xolair) and dupilumab (Dupixent), which have transformed the management of allergic diseases, including severe asthma and atopic dermatitis. New drug delivery technologies like needle-free injections, smart inhalers, and personalized vaccines are making allergy treatment more accessible, convenient, and effective. In 2021, about 81 million people in the U.S. were diagnosed with hay fever. In the same year, around 26 million Americans had allergic asthma.
Allergy Immunology Market Segmentation
By Treatment Type: Subcutaneous Immunotherapy (SCIT), or allergy shots, is a classic form of immunotherapy. It works exceptionally well for strong allergic reactions (e.g. allergic rhinitis, asthma and venom allergies). Its counterpart Sublingual Immunotherapy (SLIT) is growing in popularity in regions such as Europe and North America. Regulatory bodies in multiple regions such as North America and Europe have approved sublingual immunotherapy (SLIT) tablets for ragweed or grass pollen, contributing to market growth.
Excited to dive in? Request your sample copy of the report to uncover its contents: https://www.maximizemarketresearch.com/request-sample/37109/
Allergy Immunology Market Regional Analysis
United States: The Northeast also boasts some of the highest rates of asthma and allergic rhinitis. In the Midwest, Urban centers like Chicago and Detroit have high allergy prevalence owing to urbanization and air pollution. The South region has some of the worst rates of allergic asthma in the country, and its soaring rates of tree pollen, grass pollen, and mold add to the problem. Cities like Los Angeles and San Francisco in the West experience some of the highest rates of environmental allergies.
Germany: North Rhine-Westphalia (NRW), with cities like Cologne, Dusseldorf, and Dortmund, has one of the highest populations in Germany, contributing to a significant allergy patient pool. Southern Germany is known for its high-quality healthcare facilities, which drive the development of advanced allergy treatments. Frankfurt, located in Hessen, is one of the financial hubs of Germany and has a large population exposed to urban allergens and air pollution.
China: High rates of mold and dust mites in southern China are fueling demand for such allergen-specific immunotherapy. There is a high demand for allergy treatments resulting from respiratory illness in China, particularly in urbanized centers with high levels of air pollution like Beijing and Shanghai. Z-Western and Southwestern China have limited access to healthcare but are developing rapidly with increasing investment in healthcare.
Allergy Immunology Market Competitive Landscape
Allergopharma GmbH & Co. KG: Stallergenes Greer Global leader in allergy immunotherapy Stallergenes Greer acquired Allergopharma from Merck KGaA, Darmstadt, Germany.
Thermo Fisher Scientific Inc.: Thermo Fisher purchased Life Technologies Corporation for roughly $13.6 billion. Thermo Fisher also closed the purchase of Patheon for $7.2 billion.
Merck Group: Merck Group, the German pharmaceutical company, bought Sigma-Aldrich for $17 billion and Versum Materials for about $6.5 billion.
Recent Developments:
- Xolair, a monoclonal antibody developed by Genentech (Roche), is used in the treatment of moderate-to-severe allergic asthma and chronic hives.
- On October 12th, I discussed Zymeworks (ZYME) as a good play on the AnaptysBio (ANAB) AllergoOn biologic food allergy drug, designed to treat peanut and egg allergies.
Conclusion
- Data-driven insights, predictive analytics, and real-time monitoring also hold potential in the market for optimizing treatment plans and ultimately desensitizing patients, with a view towards sustained, long-term relief.
Related Reports:
Immunotherapy Drugs Market size was valued at USD 149.2 Billion in 2023 and the total Immunotherapy Drugs Market revenue is expected to grow at a CAGR of 10.1% from 2024 to 2030, reaching nearly USD 292.60 Billion by 2030.
Cancer Immunotherapy Market size was valued at USD 118.12 Bn. in 2023. Monoclonal Antibodies, one of the segments reviewed in our reports dominated the Cancer Immunotherapy Market.
About Us
Maximize Market Research is one of the fastest-growing market research and business consulting firms serving clients globally. Our revenue impact and focused growth-driven research initiatives make us a proud partner of majority of the Fortune 500 companies. We have a diversified portfolio and serve a variety of industries such as IT & telecom, chemical, food & beverage, aerospace & defense, healthcare and others.
Contact Us:
MAXIMIZE MARKET RESEARCH PVT. LTD.
3rd Floor, Navale IT park Phase 2,
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India.
+91 9607365656
[email protected]
Information contained on this page is provided by an independent third-party content provider. Binary News Network and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]
Comments